Mayo Clinic proceedings
-
Mayo Clinic proceedings · Dec 2024
ReviewHypertension Management in Women With a Multidisciplinary Approach.
Current clinical practice guidelines were established by several organizations to guide the diagnosis and treatment of hypertension in men and women in a similar manner despite data demonstrating differences in underlying mechanisms. Few publications have provided a contemporary and comprehensive review focused on characteristics of hypertension that are unique to women across their life spectrum. ⋯ Here, we discuss potential factors contributing to hypertension in women, differences related to effects of lifestyle modifications and drug therapy between men and women, the impact of sleep, and the importance of recognizing disparities in socioeconomic conditions and access to care. This review outlines several opportunities for future studies to fill gaps in knowledge to achieve optimal control of hypertension in women using a multidisciplinary approach, particularly related to sex-specific treatment approaches while considering socioeconomic conditions and life stages from premenopause through the transition to menopause.
-
Statins are the mainstay of cholesterol treatment to prevent atherosclerotic cardiovascular disease. However, significant barriers, including physician and patient factors, prevent the optimal use of this drug class. ⋯ Within the tips, we discuss key components of the guidelines, assessing cardiovascular risk profiles, evaluating drug-drug interactions, addressing adverse effects, and developing treatment plans that include statins and nonstatins. The tips will be useful for primary and specialty clinicians, such as cardiologists, endocrinologists, and nephrologists.
-
Mayo Clinic proceedings · Dec 2024
Characteristics of an Older Adult Population Without COVID-19 Infection in a Southeast Minnesota Community.
To assess demographic characteristics, public health measures, and health beliefs or behaviors that differentiate participants with a history of the coronavirus disease 2019 (COVID-19) infection from those with no history of COVID-19. ⋯ Depending on the communicability, virulence, and pathogenicity of future COVID-19 variants, local, state, and federal governments must continue to consider the risks and benefits of public health initiatives that take into consideration these protective factors.